Keyphrases
Laropiprant
100%
Extended-release Niacin
100%
Heart Failure Clinic
100%
Anacetrapib
100%
Niacin
50%
Major Vascular Injury
50%
Optimal Medical Therapy
37%
Merck
16%
Atherosclerotic Vascular Disease
16%
HPS2-THRIVE
16%
Arterial Revascularization
16%
Vascular Events
16%
Cholesteryl Ester Transfer Protein
16%
Cholesterol Absorption Inhibitor
16%
Intensive Statin Therapy
16%
NYHA Class
12%
Cardiovascular Admissions
12%
Time-to-event
12%
Stable Heart Failure
12%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Nicotinic Acid
100%
Laropiprant
100%
Randomized Clinical Trial
100%
Anacetrapib
100%
Combination Therapy
27%
Cholesterol Ester Transfer Protein
16%
Cholesterol Ester Transfer Protein Inhibitor
16%
Systolic Heart Failure
9%
Symptom
9%
Medicine and Dentistry
Heart Failure
100%
Randomized Clinical Trial
100%
Combination Therapy
27%
General Practitioner
27%
Cardiovascular System
9%
Patient Referral
9%
Identified Patient
9%
Quality of Life
9%
Heart Left Ventricle Ejection Fraction
9%
Outpatient
9%
Systolic Heart Failure
9%
New York Heart Association Class
9%
Symptom
9%